SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : YEEHAW CANDIDATES

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: PuddleGlum who wrote (9261)8/18/2005 9:23:27 AM
From: Galirayo  Read Replies (1) of 23958
 
[ARIA] It's Ready again.

stockcharts.com[w,a]dacayiay[db][pb50!c20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G

Market Pulse: Ariad Pharma gets orphan-drug status for cancer drug
Thursday August 18, 7:43 am ET
By Thomas Middleton

NEW YORK (MarketWatch) -- Ariad Pharmaceuticals Inc. said Thursday that AP23573, its novel mTOR inhibitor, has been designated an orphan drug by the Food and Drug Administration for the treatment of both soft-tissue and bone sarcomas. The Cambridge, Mass., company said its small-molecule drug starves cancer cells and shrinks tumors by inhibiting the critical cell-signaling protein, mTOR. Shares of Ariad last traded down 2.8% at $7.06.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext